newsfilter
← Latest News
Business Wire·

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

IMFINZI is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting DeLLphi-305 Phase III trial results reinforce IMFINZI as the backbone immunotherapy